

# Negative Regulation of AKT Activation by BRCA1

Tao Xiang,<sup>1</sup> Amiko Ohashi,<sup>1</sup> Yuping Huang,<sup>1</sup> Tej K. Pandita,<sup>1</sup> Thomas Ludwig,<sup>2</sup> Simon N. Powell,<sup>1</sup> and Qin Yang<sup>1</sup>

<sup>1</sup>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri and <sup>2</sup>Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York

## Abstract

**The breast cancer susceptibility gene 1 (*BRCA1*) plays a key role in mammary tumorigenesis. However, the reasons why silencing the *Brcal* gene leads to tumorigenesis are not clearly understood. We report here that *BRCA1* deficiency activates the AKT oncogenic pathway, one of the most common alterations associated with human malignancy. Mutation of *Brcal* gene increases the phosphorylation and the kinase activity of AKT. The *BRCA1*-BRCT domains bind to phosphorylated AKT (pAKT) and lead to its ubiquitination toward protein degradation. *BRCA1* mutant cells lacking the BRCT repeats accumulate nuclear pAKT and consequently inactivate the transcription functions of FOXO3a, a main nuclear target of pAKT. Our results show that *BRCA1* is a negative regulator of the AKT pathway and imply the significance of the *BRCA1*/AKT pathway in tumorigenesis. [Cancer Res 2008;68(24):10040–4]**

## Introduction

The breast cancer susceptibility gene 1 (*Brcal*) has been shown to play a key role in both hereditary and sporadic mammary tumorigenesis (1–3). *BRCA1* has been implicated in DNA damage repair, cell cycle checkpoint control, transcriptional regulation, and maintenance of genomic stability, which are key factors in tumorigenesis (1, 2). However, the extent to which *BRCA1*-activated molecular pathways contribute to its tumor suppressor activity remains unclear. The *BRCA1* BRCT domains are phospho-protein binding motifs that are important for the tumor suppressor function of *BRCA1* (4–6). Most *BRCA1* mutations cause truncated *BRCA1* gene products that lack one or both COOH-terminal BRCT domains. Clinically relevant missense mutations identified at the COOH terminus of *BRCA1* abolish the BRCT structure (1, 2), and *Brcal* deficiency leads to tumor formation in mice (5).

The AKT/PKB kinase is a well-characterized effector of phosphoinositide 3-kinase, and its deregulation plays an important role in the pathogenesis of human cancers. Increased AKT kinase activity has been reported in ~40% of breast and ovarian cancers (7). Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classic metabolic regulation (7, 8). A number of nonexclusive mechanisms contribute to AKT hyperactivation in human cancer (9). PTEN deficiency and *PIK3CA* and *Ras* mutations lead to AKT activation and occur frequently in human cancers. PML and PHLP also regulate the AKT pathway in

tumorigenesis (10, 11). Thus, it seems that AKT activation plays a pivotal role in the genesis of cancer.

In spite of extensive efforts studying *BRCA1* and AKT individually, an interaction of *BRCA1* and AKT has not been reported. However, several lines of evidence suggest a role for *BRCA1* in the regulation of AKT. AKT can phosphorylate *BRCA1* (12), implying that AKT may bind to *BRCA1* directly. Both AKT and *BRCA1* regulate the cell cycle and genomic stability through the CHK1 pathway (2, 13), and *BRCA1* regulates estrogen receptor- $\alpha$  activity in a phosphoinositide 3-kinase/AKT-dependent manner (14), strongly supporting the notion that the AKT pathway contributes to *BRCA1*-mediated tumorigenesis.

## Materials and Methods

**Cell culture.** Primary embryonic fibroblasts were generated from *Brcal*<sup>+/+</sup> and *Brcal*<sup>tr/tr</sup> embryos at embryonic day 13.5. Early-passage primary mouse embryonic fibroblasts (MEF) were immortalized by transfection with a plasmid expressing the SV40 large T antigen.

**RNAi.** AKT1 and *BRCA1* small interfering RNAs (siRNA) were designed in 3' untranslated region (UTR) region by Oligoengine RNAi software and synthesized by Dharmacon. Lentiviral *BRCA1*-shRNAs were from Sigma.

**In vitro AKT kinase assay.** AKT kinase activity from cell extracts was analyzed by immunoprecipitation/kinase assay (AKT Kinase Assay Kit, Cell Signaling Technology).

**In vitro protein interactions.** Glutathione *S*-transferase (GST) fusion *BRCA1* proteins were produced in *Escherichia coli* and purified according to the manufacturer's instructions (Amersham Pharmacia Biotech).

**Indirect immunofluorescence.** Images were captured and pseudocolored with IPLab image analysis software. At least 100 cells were analyzed for each experiment. The experiments were repeated at least three times.

**Ubiquitination assay.** Cells were transfected with the indicated plasmids and lysates were analyzed by immunoprecipitation and Western blot with the indicated antibodies.

The details of materials and methods are described in Supplemental data.

## Results and Discussion


***BRCA1* is a negative regulator of the AKT pathway.** Here, we reasoned that *BRCA1* might be involved in the AKT signal transduction. To examine the role of *BRCA1* in the AKT pathway, *BRCA1* was stably expressed in the breast cancer cell line HCC1937, which is hemizygous with respect to the *BRCA1* mutant allele 5382insC expressing a *BRCA1* protein lacking the COOH-terminal BRCT repeats. This mutation is associated with an increased risk of cancer and eliminates the activity of *BRCA1* in the repair of DNA damage and maintenance of genomic stability (1, 2). Phosphorylation of AKT on Thr<sup>308</sup> and Ser<sup>473</sup> is required for its full activation (7). Using antibodies specific for phospho-Ser<sup>473</sup> and Thr<sup>308</sup> AKT, we tested the phosphorylation status of AKT in HCC1937 cells with or without exogenously expressing wild-type *BRCA1*. AKT was phosphorylated on both Thr<sup>308</sup> and Ser<sup>473</sup> in HCC1937 cells (Fig. 1A). Expression of *BRCA1* reduced the phosphorylation levels of both Thr<sup>308</sup> and Ser<sup>473</sup> of AKT by ~80% (Fig. 1A). Expression of

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

**Requests for reprints:** Qin Yang, Department of Radiation Oncology, Washington University School of Medicine, 4511 Forest Park, St. Louis, MO 63108. Phone: 314-747-5445; Fax: 314-362-9790; E-mail: qyang@wustl.edu.

©2008 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-08-3009


**Figure 1.** BRCA1 is a negative regulator of the AKT kinase pathway. **A**, BRCA1 negatively regulates the phosphorylation of AKT. *Left*, lysates were prepared from HCC1937 cells (BRCA1-inactive) that stably expressed BRCA1 (+) or vector only (-) and analyzed by Western blotting with the indicated antibodies. *Right*, lysates from *Brca1<sup>+/+</sup>* or *Brca1<sup>1tr/tr</sup>* MEFs were analyzed by Western blot. **B**, increased phosphorylation of AKT in BRCA1 knockdown cells. siRNAs corresponding to the genes for the indicated proteins were transferred into MCF-7 breast cancer cells. After 2 d, lysates were prepared and analyzed by Western blot with the indicated antibodies. **C**, BRCA1 negatively regulates the AKT kinase activity. Whole-cell lysates prepared from HCC1937 cells expressing BRCA1 (+) or vector only (-) were subjected to immunoprecipitation (IP) with the anti-AKT antibody (AKT kinase kit, Cell Signaling) and analyzed by Western blot (WB) with the indicated antibodies. Insulin is a specific activator of the AKT pathway. **D**, BRCA1 negatively regulates the AKT pathway. Lysates from HCC1937 cells were analyzed by Western blot with the indicated antibodies. PDK1 is a kinase of AKT and GSK-3 $\beta$  is a downstream substrate of AKT.




AKT recognized by an antibody (Cell Signaling, #9272) showed the same level by insulin treatment when phosphorylated AKT (pAKT) increased 2- to 3-fold (Fig. 1C), suggesting that this AKT antibody mainly recognizes unphosphorylated form of AKT. These data

are consistent with published reports for using the same antibody (10, 11). Expression of BRCA1 in HCC1937 cells had no detectable effect on levels of unphosphorylated AKT detected by this antibody. Furthermore, immortalized MEFs expressing a truncated

**Figure 2.** BRCA1 interacts with pAKT. **A**, BRCA1 interacts with pAKT in cells. Lysates from MCF7 cells were treated with or without  $\lambda$  phosphatase (PPase) or phosphatase inhibitor (10 mmol/L NaF and 50 mmol/L  $\beta$ -glycerophosphate) and then subjected to immunoprecipitation, followed by Western blot with the indicated antibodies. Twenty percent input was loaded as a control. **B**, MCF7 cells were prepared at steady state (sts), starvation (sta), and serum stimulation for the times indicated. Lysates were subjected to immunoprecipitation with the anti-BRCA1 antibody, followed by Western blot with the indicated antibodies. **C**, BRCA1 interacts with pAKT *in vitro*. Lysates from MCF7 cells were incubated with various GST-BRCA1 fragments immobilized on Sepharose beads, eluted, and analyzed by Western blot with antibody against the phosphorylated or unphosphorylated form of AKT (#9272). Twenty percent input was loaded as a control. Equal loading of GST proteins was confirmed by Coomassie blue staining. **D**, BRCA1-BRCT domains interact with pAKT. Lysates were incubated with GST-BRCA1-BRCT wild-type and M1775R and P1749R mutant proteins immobilized on Sepharose beads. The complex was eluted and analyzed by Western blot with anti-pAKT antibody. Equal loading of GST proteins was confirmed by Coomassie blue staining.





**Figure 3.** BRCA1 ubiquitinates pAKT. *A*, lysates were prepared from HCC1937 cells expressing BRCA1 or vector with or without 50  $\mu\text{mol/L}$  MG132 treatment for 2 h, and analyzed by Western blot with the indicated antibodies. *B*, HCC1937 cells expressing BRCA1 or empty vector were transfected with a Myc-tagged ubiquitin plasmid in the absence or presence of 50  $\mu\text{mol/L}$  MG132 for 2 h. Lysates were analyzed by immunoprecipitation and Western blot with the indicated antibodies. *C*, 293T cells transfected with constructs expressing Myc-ubiquitin, HA-BRCA1, and HA-BRCA1-mutants were treated with 50  $\mu\text{mol/L}$  MG132 for 2 h. Lysates were analyzed by immunoprecipitation and Western blot with the indicated antibodies.  $\Delta\text{C}$ , COOH-terminal deletion of BRCA1. *C61G*, inactive E3 ubiquitin ligase of BRCA1. *M1775R*, point mutation in BRCT domains.

*Brcal* allele (*Brcal*<sup>tr/tr</sup>; ref. 5) showed higher levels of pAKT, compared with *Brcal*<sup>+/+</sup> MEFs, confirming that BRCA1 negatively regulates the phosphorylation of AKT (Fig. 1A).

Because the basal levels of pAKT are negatively regulated by PTEN, which is also deleted in HCC1937 cells, we verified that pAKT1 was regulated by BRCA1 in MCF-7 breast cancer cell line (with wild-type BRCA1 and PTEN). Knockdown of BRCA1 expression by BRCA1 siRNA and short hairpin RNA (shRNA) enhanced the amounts of pAKT (Fig. 1B; Supplementary Fig. S1A). Expression of total PTEN and phosphorylated PTEN displayed the same level in these cells (Supplementary Fig. S1B), suggesting that regulation of pAKT by BRCA1 is independent of PTEN. Knockdown of *Brcal* in MEFs with or without *Pten* gene increased the levels of pAKT (Supplementary Fig. S1C), supporting that BRCA1 independently regulates pAKT.

To detect the effect of BRCA1 on AKT kinase activity, we performed an *in vitro* AKT kinase assay by using GSK-3 fusion

protein as a substrate. Insulin is a specific activator of the AKT pathway. As expected, insulin treatment could increase AKT kinase activity (Fig. 1C). Expression of BRCA1 decreased the AKT kinase activity, correlated with a reduction of pAKT levels. Overall, these results indicate that BRCA1 negatively regulates the phosphorylation and activation of AKT.

PDK1 is a protein kinase that phosphorylates Thr<sup>308</sup> of AKT. The phosphorylation status of PDK1 in HCC1937 cells expressing BRCA1 was identical to that of control cells (Fig. 1D), suggesting that BRCA1 may regulate the AKT phosphorylation and activity by acting on factors downstream of PDK1. Furthermore, expression of BRCA1 decreased pAKT levels, which correlated with decreased phosphorylation of its substrate GSK-3 $\beta$  (Fig. 1D), implying that BRCA1 regulates AKT kinase.

**BRCA1 interacts with pAKT.** To detect that the interaction of BRCA1 and AKT is phospho-specific in cells, a coimmunoprecipitation assay was done. Lysates that had first been treated with protein phosphatase (PPase) abolished this interaction, whereas inclusion of phosphatase inhibitors in lysis buffer increased the interaction of BRCA1 with AKT (Fig. 2A). These results suggest that the BRCA1-AKT interaction depends on the phosphorylation of AKT. Immunoprecipitates by pull-down with the AKT antibody (1G1) included both phosphorylated and unphosphorylated forms of AKT (Fig. 2A, pAKT T308 and AKT #9272). Because the AKT antibody (1G1) did not work for Western blot analysis (see manufacturer's information, and data not shown), we used the AKT antibody (#9272, recognizing unphosphorylated form of AKT) to verify the immunoprecipitation assay (Fig. 2A). The results showed that the unphosphorylated form of AKT was unchanged in lysates with protein phosphatase or phosphatase inhibitor treatment. Furthermore, pAKT, but not unphosphorylated AKT, was detected in BRCA1 immunoprecipitates in MCF7 cells (Supplementary Fig. S2, left). In addition, BRCA1 was detected in pAKT immunoprecipitates in MCF7 cells (Supplementary Fig. S2, right), confirming the existence of the BRCA1/pAKT complex in cells. Association of pAKT with BRCA1 was increased after serum stimulation (Fig. 2B), further confirming that the BRCA1-AKT interaction depends on the phosphorylation of AKT.


Next, we investigated the binding domains of BRCA1 with AKT using an *in vitro* binding assay. A series of four overlapping GST fusion proteins, spanning the entire coding region of BRCA1, were used to define regions of BRCA1 that interact with AKT. Purified GST-BRCA1 fusion proteins were added to MCF7 cell-free extracts, and GST-BRCA1-AKT complexes were isolated with glutathione beads. pAKT, but not unphosphorylated AKT, was found to bind fragment 1501–1861 of BRCA1 as detected by Western blotting (Fig. 2C). BRCA1 fragment 1501–1861 contains the BRCT domains, which are phospho-protein binding domains that are important for the tumor suppressor function of BRCA1. The recombinant BRCA1-BRCT domain (residues 1599–1863) fused to GST-bound endogenous pAKT from a MCF7 cell lysate (Fig. 2D). The cancer-associated missense mutations M1775R and P1749R in the BRCT domains of the COOH terminus of BRCA1 ablate the functions of BRCA1 (2). We tested the binding ability of these BRCA1 mutants to pAKT and both failed to interact with pAKT (Fig. 2D), suggesting that the intact structure of the tandem BRCA1-BRCT domains is essential for its interaction with pAKT.

**BRCA1 ubiquitinates the pAKT leading to its degradation.** Recent reports indicate that BRCA1 and its partner BARD1 are enzymatic mediators of protein ubiquitination (15, 16). The potent ubiquitin E3 ligase activity of the BRCA1/BARD1 heterodimer may

be responsible for the inactivation of pAKT by BRCA1. To test this possibility, we used MG132, a proteasome inhibitor. pAKT levels increased in HCC1937 cells expressing BRCA1 or in *Brca1*<sup>+/+</sup> MEFs when treated with MG132 (Fig. 3A; Supplementary Fig. S3), suggesting that the BRCA1-dependent ubiquitination may cause the degradation of pAKT. To further investigate this possibility, we transfected an ubiquitin expression plasmid in HCC1937 cells and found that BRCA1 stimulated the ubiquitination of pAKT in HCC1937 cells expressing BRCA1 (Fig. 3B). Polyubiquitination often serves as a signal for the protein degradation. To characterize the potential biological consequences of the ubiquitinated pAKT, we compared the stability of pAKT in cells treated with MG132. Treatment with MG132 stabilized the ubiquitinated pAKT and resulted in longer chains of ubiquitin appended on pAKT (Fig. 3B), suggesting that BRCA1-dependent ubiquitination causes the degradation of pAKT. It has been shown that expression of BRCA1 in cells stimulates the ubiquitination of phosphorylated RNA polymerase II (17). Using this system, BRCA1 and ubiquitin expression constructs were transfected into

293T cells. Transfected wild-type BRCA1 stimulated the ubiquitination of pAKT, but BRCA1 constructs lacking the BRCT repeats ( $\Delta$ C) or encoding disease-associated missense mutation (M1775R) did not. To further detect the effect of BRCA1/BARD E3 ubiquitin ligase activity on pAKT ubiquitination, a C61G mutant of BRCA1 that has inactive E3 was tested. Cells expressing the C61G mutant did not show the ubiquitination signals of pAKT (Fig. 3C), indicating that the BRCA1 associated E3 ubiquitin ligase activity is required for the ubiquitination of pAKT. Furthermore, the COOH-terminal deletion ( $\Delta$ C) or M1775R mutation disrupted BRCA1 binding to pAKT, as analyzed by coimmunoprecipitation assays (Supplementary Fig. S4). Thus, intact BRCT domains are required for the binding of pAKT to BRCA1 for its degradation in cells, consistent with our results from the *in vitro* binding assays.

**BRCA1 deficiency leads to an increased nuclear localization of pAKT.** After phosphorylation and activation on the membrane, pAKT is released into the cytoplasm and translocated to the nucleus (7). Furthermore, BRCA1 is a nuclear-cytoplasmic shuttling



**Figure 4.** BRCA1 deficiency leads to increased nuclear localization of pAKT. *Brca1*<sup>+/+</sup> and *Brca1*<sup>tr/tr</sup> MEFs were prepared at steady state, starvation, and serum stimulation for the times indicated. *A*, immunofluorescence staining; *B*, Western blot analysis. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). *C*, the expression levels of FOXO3a were decreased in nuclear extracts from *Brca1*<sup>tr/tr</sup> MEFs, analyzed by Western blot (top). Expressing the AKT1-S473D mutant resulted in the decrease of FOXO3a in *Brca1*<sup>tr/tr</sup> MEFs (bottom). Nuclear extracts from *Brca1*<sup>tr/tr</sup> MEFs transfected with the indicated plasmids were analyzed by Western blot. AKT1 siRNA targeted on the 3' UTR region of AKT1 and only decreased the expression of endogenous AKT1 but did not affect the expression of the transfected flag-AKT1. Lanes 3 to 5, with the AKT antibody showing the transfected flag-AKT1. WT, wild-type *Brca1* plasmid; Mu, *Brca1*-BRCT mutant (M1775R, point mutation in BRCT domains). *D*, BRCA1 affects FOXO3a activity via the AKT pathway. mRNA levels of *p27*<sup>kip1</sup> in *Brca1*<sup>tr/tr</sup> MEFs transfected with the indicated plasmids or siRNAs were measured by real-time PCR. Bars, SD of triplicates.

protein, and cancer-associated mutations in the BRCT domains alter subcellular localization of BRCA1 (18). To test whether BRCA1 regulates the localization of pAKT, we used *Brcal*<sup>+/+</sup> and *Brcal*<sup>tr/tr</sup> MEFs. First, we determined AKT status in *Brcal*<sup>+/+</sup> and *Brcal*<sup>tr/tr</sup> MEFs by subjecting them to serum starvation and stimulation. *Brcal*<sup>tr/tr</sup> cells showed stronger pAKT staining in both cytoplasm and nuclei at steady state and serum stimulation (Fig. 4A). Treatment with MG132 increased pAKT staining in *Brcal*<sup>+/+</sup> MEFs, consistent with the observations by Western blotting (Fig. 3). To confirm these observations, cytoplasmic and nuclear fractions were prepared from these cells and analyzed by Western blotting. Increased pAKT levels were found in the cytoplasm and nuclei of *Brcal*<sup>tr/tr</sup> cells compared with *Brcal*<sup>+/+</sup> cells (Fig. 4B). These observations indicate that the absence of full-length BRCA1 protein leads to an increased nuclear localization of pAKT.

**Interaction of pAKT-BRCA1 mediates the AKT1-FOXO pathway.** The forkhead transcription factor FOXO3a is a direct nuclear target of AKT, as AKT-mediated phosphorylation causes FOXO3a inactivation and nuclear export (19, 20). To test whether BRCA1 deficiency enhances the nuclear function of pAKT, we next examined effects of BRCA1-pAKT interaction on FOXO3a inactivation and nuclear export. We found that the levels of FOXO3a decreased in nuclear extracts from *Brcal*<sup>tr/tr</sup> MEFs (Fig. 4C, top), suggesting that BRCA1 deficiency causes FOXO3a nuclear export by activating the AKT pathway. An AKT1-S473D mutant, bound only to wild-type BRCA1 protein but not to the BRCA1-BRCT mutant (Supplementary Fig. S5), was expressed in *Brcal*<sup>tr/tr</sup> MEFs, resulting in the decrease of FOXO3a (Fig. 4C, bottom). Cotransfected wild-type BRCA1, but not BRCA1-BRCT mutant, abolished the effect of AKT1-S473D, confirming that BRCA1 regulates the pAKT-mediated FOXO3a nuclear export. FOXO3a exerts some of its tumor-suppressive functions by inducing the transcription of *p27<sup>kip1</sup>* (19). As quantified by real-time PCR, overexpression of

AKT1-S473D decreased *p27<sup>kip1</sup>* mRNA levels in *Brcal*<sup>tr/tr</sup> MEFs (Fig. 4D). Cotransfected wild-type BRCA1 could block the effect of AKT1-S473D, whereas the BRCA1-BRCT mutant could not, due to the lack of interaction with pAKT. Thus, we show that interaction of pAKT-BRCA1 regulates the transcription function of FOXO3a.

The role of the BRCA1-AKT interaction in tumorigenesis is a novel finding. Establishment of this novel BRCA1-AKT pathway and the elucidation of its precise molecular functions are expected to improve our understanding of hereditary as well as sporadic mammary tumorigenesis. Targeting the BRCA1/AKT pathway may lead to the improved design of highly specific molecular targeted therapies with efficacy and reduced toxicity for BRCA1-deficient cancers.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

Received 8/5/2008; revised 9/22/2008; accepted 9/24/2008.

**Grant support:** Susan G. Komen Foundation (Q. Yang), the Ovarian Cancer Research Fund (Q. Yang), Siteman Cancer Center Award (Q. Yang), and NIH grants CA 10445 and CA 123232 (T.K. Pandita).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Tanya T. Paull (Department of Molecular Genetics and Microbiology, University of Texas, Austin, TX) and Stephen J. Elledge (Department of Genetics, Harvard University Medical School, Boston, MA) for providing the GST-BRCA1 constructs, Junjie Chen (Therapeutic Radiology and Pathology, Yale University, New Haven, CT) for providing the wild-type and mutant GST-BRCA1-BRCT constructs, Natsuko Chiba (Department of Clinical Oncology, Tohoku University, Sendai, Japan) and Jeffrey D. Parwin (Department of Pathology, Harvard University Medical School, Boston, MA) for providing the Myc-ubiquitin and wild-type and mutant BRCA1 constructs, and Bing-Hua Jiang (Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV) for providing the AKT1-473D construct.

## References

- Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. *Mol Cancer Res* 2005;3:531-9.
- Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. *Nat Rev Cancer* 2004;4:665-76.
- McCoy ML, Mueller CR, Roskelley CD. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. *Reprod Biol Endocrinol* 2003;1:72.
- Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. *Science* 2003;302:639-42.
- Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncating *Brcal* mutation. *Genes Dev* 2001;15:1188-93.
- Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. *Science* 2003;302:636-9.
- Bellacosa A, Kumar CC, Di CA, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. *Adv Cancer Res* 2005;94:29-86.
- Cantley LC. The phosphoinositide 3-kinase pathway. *Science* 2002;296:1655-7.
- Hay N. The Akt-mTOR tango and its relevance to cancer. *Cancer Cell* 2005;8:179-83.
- Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. *Mol Cell* 2005;18:13-24.
- Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. *Nature* 2006;441:523-7.
- Miralem T, Avraham HK. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. *Mol Cell Biol* 2003;23:579-93.
- Shtivelman E, Sussman J, Stokoe D. A role for PI 3-kinase and PKB activity in the G<sub>2</sub>/M phase of the cell cycle. *Curr Biol* 2002;12:919-24.
- Ma Y, Hu C, Riegel AT, Fan S, Rosen EM. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor- $\alpha$  activity. *Mol Endocrinol* 2007;21:1905-23.
- Starita LM, Parvin JD. Substrates of the BRCA1-Dependent Ubiquitin Ligase. *Cancer Biol Ther* 2006;5:137-41.
- Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. *Curr Opin Genet Dev* 2002;12:86-91.
- Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. *J Biol Chem* 2005;280:24498-505.
- Rodriguez JA, Au WW, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. *Exp Cell Res* 2004;293:14-21.
- Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. *Sci STKE* 2003;2003:RE5.
- Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 1999;96:857-68.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

**AACR** American Association  
for Cancer Research

## Negative Regulation of AKT Activation by BRCA1

Tao Xiang, Amiko Ohashi, Yuping Huang, et al.

*Cancer Res* 2008;68:10040-10044.

<b>Updated version</b>	Access the most recent version of this article at: <a href="http://cancerres.aacrjournals.org/content/68/24/10040">http://cancerres.aacrjournals.org/content/68/24/10040</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2008/12/12/68.24.10040.DC1">http://cancerres.aacrjournals.org/content/suppl/2008/12/12/68.24.10040.DC1</a>

<b>Cited articles</b>	This article cites 20 articles, 7 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/68/24/10040.full#ref-list-1">http://cancerres.aacrjournals.org/content/68/24/10040.full#ref-list-1</a>
<b>Citing articles</b>	This article has been cited by 12 HighWire-hosted articles. Access the articles at: <a href="http://cancerres.aacrjournals.org/content/68/24/10040.full#related-urls">http://cancerres.aacrjournals.org/content/68/24/10040.full#related-urls</a>

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cancerres.aacrjournals.org/content/68/24/10040">http://cancerres.aacrjournals.org/content/68/24/10040</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.